These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 17690880)
1. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880 [TBL] [Abstract][Full Text] [Related]
2. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Kurosaki M; Horiguchi S; Yamasaki K; Uchida Y; Motohashi S; Nakayama T; Sugimoto A; Okamoto Y Cancer Immunol Immunother; 2011 Feb; 60(2):207-15. PubMed ID: 20978887 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288 [TBL] [Abstract][Full Text] [Related]
4. Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy. Okamoto Y; Fujikawa A; Kurosaki M; Yamasaki K; Sakurai D; Horiguchi S; Nakayama T Adv Otorhinolaryngol; 2011; 72():149-52. PubMed ID: 21865716 [TBL] [Abstract][Full Text] [Related]
5. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261 [TBL] [Abstract][Full Text] [Related]
6. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787 [TBL] [Abstract][Full Text] [Related]
7. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells. Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247 [TBL] [Abstract][Full Text] [Related]
9. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. Fujii S; Shimizu K; Steinman RM; Dhodapkar MV J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720 [TBL] [Abstract][Full Text] [Related]
10. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer. Takami M; Ihara F; Motohashi S Front Immunol; 2018; 9():2021. PubMed ID: 30245690 [TBL] [Abstract][Full Text] [Related]
11. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer. Ishibashi F; Sakairi Y; Iwata T; Moriya Y; Mizobuchi T; Hoshino H; Yoshida S; Hanaoka H; Yoshino I; Motohashi S Clin Immunol; 2020 Jun; 215():108457. PubMed ID: 32387537 [TBL] [Abstract][Full Text] [Related]
12. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy]. Motohashi S Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340 [TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells. Nicol AJ; Tazbirkova A; Nieda M Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690 [TBL] [Abstract][Full Text] [Related]
14. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616 [TBL] [Abstract][Full Text] [Related]
15. Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ. Shimizu K; Hidaka M; Bickham K; Moriwaki M; Fujimoto K; Kawano F; Fujii S Int J Hematol; 2010 Jul; 92(1):152-60. PubMed ID: 20552304 [TBL] [Abstract][Full Text] [Related]
16. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688 [TBL] [Abstract][Full Text] [Related]
17. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949 [TBL] [Abstract][Full Text] [Related]
18. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Okai M; Nieda M; Tazbirkova A; Horley D; Kikuchi A; Durrant S; Takahashi T; Boyd A; Abraham R; Yagita H; Juji T; Nicol A Vox Sang; 2002 Oct; 83(3):250-3. PubMed ID: 12366768 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017 [TBL] [Abstract][Full Text] [Related]
20. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]